Latest News

(UroToday.com) In the Presidential Symposium 2 of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Daniel Petrylak presented results of the CheckMate 9KD cohort A2 final analysis assessing nivolumab + rucaparib for men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC).

(UroToday.com) In the Presidential Symposium 2 of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Mark Markowski presented data from a phase 1/2 trial of sabizabulin in men with metastatic castration resistant prostate cancer (mCRPC).

(UroToday.com) Following presentations from Dr. Fizazi discussing the role of abiraterone in combination with docetaxel for men with metastatic castration sensitive prostate cancer (mCSPC) and Dr. Attard discussing its role in combination with ADT for men being treated for high-risk, non-metastatic prostate cancer, Dr. Eleni Efstathiou provided an invited discussion to contextualize these results in the […]

(UroToday.com) In the Presidential Symposium 2 of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Karim Fizazi presented the results of PEACE-1 assessing the role of abiraterone acetate plus prednisone in men with de novo metastatic castration-sensitive prostate cancer (mCSPC).

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer mini oral session included a presentation by Dr. Karim Fizazi discussing health-related quality of life, pain, and safety outcomes in the phase 3 VISION study. [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) delivers β-particle radiation to prostate-specific membrane antigen (PSMA) expressing cells and the surrounding microenvironment. In the […]

(UroToday.com) In the Presidential Symposium 2 of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Gerhardt Attard presented a combined analysis from the STAMPEDE platform assessing the role of abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer mini oral session included a presentation by Dr. Richard Cathomas discussing the phase II SAAK 08/16 trial assessing darolutamide maintenance in men with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent taxane therapy. The […]

(UroToday.com) Day 2 of the 7th Annual Albert Institute for Bladder Cancer Care and Research Symposium began with a session on bladder cancer metastases. Metastasis is the primary cause of cancer morbidity and mortality and the process involves a complex interplay between intrinsic tumour cell properties and interactions between tumour cells and multiple microenvironments.1

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer proffered paper session included a presentation by Dr. Janet Brown discussing results of the phase II/III STAR trial assessing standard first-line therapy comparing cessation of treatment versus allowing continuation in the treatment of metastatic renal cell carcinoma (RCC). There is increasing interest in […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer proffered paper session included a presentation by Dr. Toni Choueiri discussing patient-reported outcomes (PROs) among patients in KEYNOTE-564 receiving pembrolizumab versus placebo as adjuvant therapy for renal cell carcinoma (RCC). Nephrectomy is the standard of care treatment for locoregional RCC, but nearly half […]